These proteins have tandem bromodomains (BD1 and BD2) that regulate gene expression through recognition of acetylated histone lysine residues, and disruption of this association by BET inhibitors is a promising approach in cancer drug discovery and development (see Reference [139] for a review of bromodomains as a drug target). The gene discussed is DNER; the disease is cancer.